Telligen’s Data Identified At-Risk Program
December 17, 2015
Did You Know?
- Individuals with multiple metabloc risk factors are three times as likely to have a heart attack or stroke1
- The presence of multiple metabolic risk factors is thought to be one of the drivers of the growing problem of diabetes and cardiovascular disease1
- It is estimated that nearly 25% of the U.S. population suffers from the presence of multiple metabolic risk factors2
Telligen offers a unique program to address members with metabolic risk factors. We identify and work with members who are currently in a “pre” disease state to prevent them from moving to a disease state. Through education support and coaching tailored to the member’s specific risk factors, Telligen’s coaches work to slow the progression toward a disease state.
The Data Identified At-Risk Program works with members who are not typically supported by disease management programs today and need more intensive coaching than what wellness programming provides. Our evidence-based coaching teaches healthy behaviors and how to sustain them to lead to a healthier workforce and potential avoidance of high medical costs.
How the Program Works
- Analysis of biometric and claims data
- Identification of members with 3 or more risk factors or in a “pre” disease state
- Evidence-based coaching (assessments, educational materials)
- Provider collaboration
- Outcomes measured by impact on prevention and lowering of those member in an at-risk state
The Telligen Difference
- Enhanced treatment of metabolic syndrome above traditional wellness coaching
- Our over 170 IT professionals and 300 medical professional work together to drive measurable outcomes
- Data driven and evidence-based medicine approach
- 40 years of proven success in impacting our clients’ outcomes and assisting in managing their costs
1Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2 Ford ES, Giles, WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287:356-359.